ZBIO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Zenas BioPharma submits BLA to FDA for obexelimab in IgG4-related diseaseMay 28, 2026
- Zenas BioPharma dosed the first participant in a Phase 1 trial of oral IL-17 inhibitor ZB021May 13, 2026
- Zenas BioPharma announces positive Phase 3 INDIGO trial results for obexelimab in IgG4-related diseaseJan 5, 2026
- Zenas BioPharma partner InnoCare achieves primary endpoint in Phase 2b orelabrutinib study for lupusDec 15, 2025
- Zenas BioPharma announces positive results from Phase 2 MoonStone trial of Obexelimab in relapsing multiple sclerosisOct 27, 2025